Media release

COVIRIX Medical / DiaCarta

8 June 2022

Melbourne, Australia / Los Angeles, USA / Bangalore, India

COVIRIX Medical ("COVIRIX Medical") and **DiaCarta** ("DiaCarta") are pleased to announce that the two companies have entered into an agreement to establish a strategic global partnership ("Partnership"). The Partnership will combine the two companies' products and services to roll out a one stop Test To Treat strategy to expedite a global solution against the Covid Pandemic.

Recently the US government has rolled out a Test To Treat strategy across the US at 33,000 locations of pharmacies and outpatient clinics. The objective is to provide a one stop detection and immediate treatment to people infected with Covid. This strategy will ensure that people infected with Covid will be prescribed the antiviral treatment immediately. The Test To Treat strategy will help treat and reduce the onset of severe diseases, and alleviate Long Covid and the burden on the healthcare system.

The Partnership will roll out its Test To Treat strategy globally initially with the Indian subcontinent and firstly in Nepal where COVIRIX Medical has planned to conduct clinical trials of its primary drug candidate CVX-20733. Patients will be tested with DiaCarta's Covid tests and if positive, they will join the clinical trials to receive the COVIRIX Medical antiviral treatment. COVIRIX Medical has been given the blessing by the Nepal Drug regulatory Agency on the implementation of this Test To Treat strategy in Nepal. The Nepalese Test To Treat model will then be replicated in other countries.

COVIRIX Medical plans to secure regulatory approval for its Covid antiviral treatment with the US FDA as Breakthrough Therapy or Investigational New Drug (IND). Under the Partnership Agreement, DaCarta will assist and support COVIRIX Medical to clinically validate the treatment under Laboratory Developed Test (LDT) program for the approval of COVIRIX Medical's Covid antiviral treatment with the US FDA. Securing the FDA approval will help expedite the approved use of COVIRIX Medical's antiviral treatment to support the Test To Treat Program in the US.

About DiaCarta

DiaCarta, a translational genomics and precision molecular diagnostics company, was established in 2011 to provide highly sensitive and advanced technologies that will improve the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. With over 80 global patents, DiaCarta offers a range of products and services, from single-gene cancer mutation detection qPCR assays, colorectal cancer mutation detection panels, radiation therapy toxicity monitoring cfDNA test to its targeted NGS panels.

DiaCarta offers a COVID-19 total solution to support the fight against COVID-19, including the RT-PCR test, antibody IgG test and CLIA lab service. Based on FDA Report, DiaCarta COVID-19 Tests Rank Top 3 Among FDA SARS-CoV-2 Reference Panel Tests. DiaCarta's COVID-19 Test Ranks Top 10 among All FDA EUA Tests Based on Limit of Detection.

CIO Bulletin has named DiaCarta among the 30 Fastest Growing Companies of 2018. DiaCarta has also been recognized as one of the Top 10 In-Vitro Diagnostic Technology Solution Providers 2018 by Med Tech Outlook Magazine.

DiaCarta's shareholders include significant institutional investor including BioVeda China Fund, Fortune Fountain Capital Financial Group, Good Health Capital, and the Bill and Melinda Gates Foundation.

About COVIRIX Medical

COVIRIX Medical is an Australia-based clinical-stage pharmaceutical company which is repositioning an existing antiviral agent, CVX-20733, as a COVID-19 therapeutic. CVX-20733 has a proven dual-action mechanism and an established safety profile to be delivered in an inhalable form, to prevent and treat the COVID-19 virus irrespective of the variant. COVIRIX Medical was formed in 2020 to bridge the gap in treatment options for the COVID-19 virus, as recognised by the highly experienced founding team. A provisional patent has been filed and published for a number of drug candidates in 11 different jurisdictions.

The management team has a range of complementary expertise that will underwrite the successful delivery of an effective Covid treatment solution. The

team includes a Chief Virologist (and head of Clinical Development) who has previously led the development of Relenza, the first neuraminidase inhibitor for Influenza, and the first point-of-care diagnostic test for Influenza A and B, a medicinal and drug development chemist, two cardiovascular physicians, an investment banker and a pharmaceutical industry aerosol expert consultant who has formulated and designed aerosol inhalers for countless products.

Its scientific advisory board includes Professor Tim Block, president of the Blumberg Institute and Hepatitis B Foundation, and Professor Yanming Du, director of medicinal chemistry at the Blumberg Institute.

COVIRIX Medical is planning to list on a major stock exchange in Australia, and Asia in 2022/2023.